Blog
RSS FeedPosted by Michael Wonder on 31 May 2023
145,000 people in England to have further treatment choice for preventing migraine attacks
31 May 2023 - NICE has for the first time recommended an oral treatment for preventing migraines. ...
Posted by Michael Wonder on 30 May 2023
Family seek to raise money for lung cancer drug
29 May 2023 - A family has raised £12,000 to pay for a cancer drug for their mother, which was ...
Posted by Michael Wonder on 29 May 2023
NICE welcomes life sciences review recommendations
26 May 2023 - NICE’s priority is to get the best care to patients fast while ensuring value for the ...
Posted by Michael Wonder on 23 May 2023
Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
22 May 2023 - More than 47,000 new cases of prostate cancer are diagnosed every year in England. ...
Posted by Michael Wonder on 19 May 2023
NICE recommends Rinvoq (upadacitinib) as a treatment option for moderately to severely active Crohn’s disease
18 May 2023 - The NICE recommendation is based on data from three Phase 3 clinical trials demonstrating upadacitinib achieved ...
Posted by Michael Wonder on 18 May 2023
NICE draft guidance recommends new treatment for chronic heart failure
18 May 2023 - Up to 150,000 people in England with a type of chronic heart failure are set to ...
Posted by Michael Wonder on 17 May 2023
Difelikefalin acetate for the treatment of patients with pruritus undergoing haemodialysis
17 May 2023 - NICE has published evidence-based recommendations on the use of difelikefalin acetate (Kapruvia) for the treatment of ...
Posted by Michael Wonder on 17 May 2023
Ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma
17 May 2023 - NICE is unable to make a recommendation on the use of ciltacabtagene autoleucel (Carvykti) for the treatment ...
Posted by Michael Wonder on 17 May 2023
Risankizumab for previously treated moderately to severely active Crohn's disease
17 May 2023 - NICE has published evidence-based recommendations on the use of risankizumab (Skyrizi) for patients 16 years of ...
Posted by Michael Wonder on 14 May 2023
Negotiations begin for a new medicine pricing scheme
4 May 2023 - Negotiations for a new voluntary scheme for branded medicines pricing to open between the government, NHS ...
Posted by Michael Wonder on 10 May 2023
Olaparib for previously treated BRCA mutation positive hormone-relapsed metastatic prostate cancer
10 May 2023 - NICE has published evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate ...
Posted by Michael Wonder on 10 May 2023
Olaparib for adjuvant treatment of BRCA mutation positive HER2 negative high-risk early breast cancer after chemotherapy
10 May 2023 - NICE has published evidence-based recommendations on olaparib (Lynparza) for adjuvant treatment of BRCA mutation positive HER2 ...
Posted by Michael Wonder on 09 May 2023
Nirmatrelvir and ritonavir for treating COVID-19
4 May 2023 - NICE is conducting a partial rapid review of TA878. ...
Posted by Michael Wonder on 09 May 2023
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies
9 May 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using belantamab ...
Posted by Michael Wonder on 04 May 2023
Access to cancer medicines in the UK
1 May 2023 - On 31 January 2020, the UK formally ended it's 47 year membership of the EU. As a ...